Burden of Illness Study among Patients with Narcolepsy or Idiopathic Hypersomnia in Japan

Burden of Illness Study among Patients with Narcolepsy or Idiopathic Hypersomnia in Japan - Burden of Illness Study among Patients with Narcolepsy or Idiopathic Hypersomnia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059563

Enrollment

300

Registered

2025-11-01

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Narcolepsy, Idiopathic hypersomnia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Having a self-reported diagnosis of narcolepsy or IH 2. Aged 18 years or older at the time of enrolment into study 3. Can read and understand Japanese 4. Willing to participate in the study and complete the questionnaire, and have accepted the informed consent form

Exclusion criteria

Exclusion criteria: Currently enrolled in any clinical trial

Design outcomes

Primary

Measure	Time frame
Total Cost and Health utilities	—

Secondary

Measure	Time frame
- Estimate the association between symptoms and costs and health utilities, among patients with NT1, NT2, and IH. - Describe HCRU in relation to disease type and severity measured by JESS, among patients with NT1, NT2, and IH. - Investigate the association of disease severity measured by JESS with education, work status, and work performance, among patients with NT1, NT2, and IH. - Describe the impact of disease severity measured by JESS on ability to operate motor vehicles, among patients with NT1, NT2, and IH.	—

Measure

Time frame

- Estimate the association between symptoms and costs and health utilities, among patients with NT1, NT2, and IH. - Describe HCRU in relation to disease type and severity measured by JESS, among patients with NT1, NT2, and IH. - Investigate the association of disease severity measured by JESS with education, work status, and work performance, among patients with NT1, NT2, and IH. - Describe the impact of disease severity measured by JESS on ability to operate motor vehicles, among patients with NT1, NT2, and IH.

—

Countries

Japan

Contacts

Public ContactYu Osada

Takeda Pharmaceutical Company Limited Japan Medical Office

yu.osada@takeda.com03-3278-2111

Outcome results